長鏈非編碼RNA與甲狀腺癌發生發展關系的研究進展及其臨床價值_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

 張浩 , 孫威

中國醫科大學附屬第一醫院甲狀腺外科（沈陽 110001）;

Corresponding?author：

張浩, Email: haozhang@cmu.edu.cn

Keywords：

DOI：

10.7507/1007-9424.201808107

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 張浩, 孫威. 長鏈非編碼RNA與甲狀腺癌發生發展關系的研究進展及其臨床價值. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2018, 25(10): 1161-1164. doi: 10.7507/1007-9424.201808107 Copy

1.	Fr?hlich E, Wahl R. The current role of targeted therapies to induce radioiodine uptake in thyroid cancer. Cancer Treat Rev, 2014, 40(5): 665-674.
2.	Ponting CP, Oliver PL, Reik W. Evolution and functions of long noncoding RNAs. Cell, 2009, 136(4): 629-641.
3.	Klinge CM. Non-coding RNAs: long non-coding RNAs and microRNAs in endocrine-related cancers. Endocr Relat Cancer, 2018, 25(4): R259-R282.
4.	Zhang R, Hardin H, Chen J, et al. Non-coding RNAs in thyroid cancer. Endocr Pathol, 2016, 27(1): 12-20.
5.	Clemson CM, Hutchinson JN, Sara SA, et al. An architectural role for a nuclear noncoding RNA: NEAT1 RNA is essential for the structure of paraspeckles. Mol Cell, 2009, 33(6): 717-726.
6.	Yu X, Li Z, Zheng H, et al. NEAT1: a novel cancer-related long non-coding RNA. Cell Prolif, 2017, 50(2): e12329.
7.	Li JH, Zhang SQ, Qiu XG, et al. Long non-coding RNA NEAT1 promotes malignant progression of thyroid carcinoma by regulating miRNA-214. Int J Oncol, 2017, 50(2): 708-716.
8.	Zhang H, Cai Y, Zheng L, et al. Long noncoding RNA NEAT1 regulate papillary thyroid cancer progression by modulating miR-129-5p/KLK7 expression. J Cell Physiol, 2018, 233(10): 6638-6648.
9.	Sun W, Lan X, Zhang H, et al. NEAT1_2 functions as a competing endogenous RNA to regulate ATAD2 expression by sponging microRNA-106b-5p in papillary thyroid cancer. Cell Death Dis, 2018, 9(3): 380.
10.	Zhang R, Hardin H, Huang W, et al. MALAT1 long non-coding RNA expression in thyroid tissues: analysis by in situ hybridization and real-time PCR. Endocr Pathol, 2017, 28(1): 7-12.
11.	Chu YH, Hardin H, Schneider DF, et al. MicroRNA-21 and long non-coding RNA MALAT1 are overexpressed markers in medullary thyroid carcinoma. Exp Mol Pathol, 2017, 103(2): 229-236.
12.	Huang JK, Ma L, Song WH, et al. MALAT1 promotes the proliferation and invasion of thyroid cancer cells via regulating the expression of IQGAP1. Biomed Pharmacother, 2016, 83: 1-7.
13.	Huang JK, Ma L, Song WH, et al. LncRNA-MALAT1 promotes angiogenesis of thyroid cancer by modulating tumor-associated macrophage FGF2 protein secretion. J Cell Biochem, 2017, 118(12): 4821-4830.
14.	Flockhart RJ, Webster DE, Qu K, et al. BRAF^V600E remodels the melanocyte transcriptome and induces BANCR to regulate melanoma cell migration. Genome Res, 2012, 22(6): 1006-1014.
15.	Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer, 2013, 13(3): 184-199.
16.	Wang Y, Guo Q, Zhao Y, et al. BRAF-activated long non-coding RNA contributes to cell proliferation and activates autophagy in papillary thyroid carcinoma. Oncol Lett, 2014, 8(5): 1947-1952.
17.	Wang Y, Gu J, Lin X, et al. lncRNA BANCR promotes EMT in PTC via the Raf/MEK/ERK signaling pathway. Oncol Lett, 2018, 15(4): 5865-5870.
18.	Zheng H, Wang M, Jiang L, et al. BRAF-activated long noncoding RNA modulates papillary thyroid carcinoma cell proliferation through regulating thyroid stimulating hormone receptor. Cancer Res Treat, 2016, 48(2): 698-707.
19.	Liao T, Qu N, Shi RL, et al. BRAF-activated LncRNA functions as a tumor suppressor in papillary thyroid cancer. Oncotarget, 2017, 8(1): 238-247.
20.	Liu L, Yang J, Zhu X, et al. Long noncoding RNA H19 competitively binds miR-17-5p to regulate YES1 expression in thyroid cancer. FEBS J, 2016, 283(12): 2326-2339.
21.	Liu N, Zhou Q, Qi YH, et al. Effects of long non-coding RNA H19 and microRNA let7a expression on thyroid cancer prognosis. Exp Mol Pathol, 2017, 103(1): 71-77.
22.	Wang P, Liu G, Xu W, et al. Long noncoding RNA H19 inhibits cell viability, migration, and invasion via downregulation of IRS-1 in thyroid cancer cells. Technol Cancer Res Treat, 2017, 16(6): 1102-1112.
23.	Lan X, Sun W, Dong W, et al. Downregulation of long noncoding RNA H19 contributes to the proliferation and migration of papillary thyroid carcinoma. Gene, 2018, 646: 98-105.
24.	Pan W, Zhou L, Ge M, et al. Whole exome sequencing identifies lncRNA GAS8-AS1 and LPAR4 as novel papillary thyroid carcinoma driver alternations. Hum Mol Genet, 2016, 25(9): 1875-1884.
25.	Zhang D, Liu X, Wei B, et al. Plasma lncRNA GAS8-AS1 as a potential biomarker of papillary thyroid carcinoma in Chinese patients. Int J Endocrinol, 2017, 2017: 2645904.
26.	Qin Y, Sun W, Zhang H, et al. LncRNA GAS8-AS1 inhibits cell proliferation through ATG5-mediated autophagy in papillary thyroid cancer. Endocrine, 2018, 59(3): 555-564.
27.	Jendrzejewski J, He H, Radomska HS, et al. The polymorphism rs944289 predisposes to papillary thyroid carcinoma through a large intergenic noncoding RNA gene of tumor suppressor type. Proc Natl Acad Sci U S A, 2012, 109(22): 8646-8651.
28.	Jendrzejewski J, Thomas A, Liyanarachchi S, et al. PTCSC3 is involved in papillary thyroid carcinoma development by modulating S100A4 gene expression. J Clin Endocrinol Metab, 2015, 100(10): E1370-E1377.
29.	Wang X, Lu X, Geng Z, et al. LncRNA PTCSC3/miR-574-5p governs cell proliferation and migration of papillary thyroid carcinoma via Wnt/β-catenin signaling. J Cell Biochem, 2017, 118(12): 4745-4752.
30.	Wang XM, Liu Y, Fan YX, et al. LncRNA PTCSC3 affects drug resistance of anaplastic thyroid cancer through STAT3/INO80 pathway. Cancer Biol Ther, 2018, 19(7): 590-597.
31.	Lan X, Zhang H, Wang Z, et al. Genome-wide analysis of long noncoding RNA expression profile in papillary thyroid carcinoma. Gene, 2015, 569(1): 109-117.
32.	Lan X, Sun W, Zhang P, et al. Downregulation of long noncoding RNA NONHSAT037832 in papillary thyroid carcinoma and its clinical significance. Tumour Biol, 2016, 37(5): 6117-6123.
33.	Sun W, Lan X, Wang Z, et al. Overexpression of long non-coding RNA NR_036575.1 contributes to the proliferation and migration of papillary thyroid cancer. Med Oncol, 2016, 33(9): 102.
34.	Qiu ZL, Shen CT, Sun ZK, et al. Circulating long non-coding RNAs act as biomarkers for predicting ¹³¹I uptake and mortality in papillary thyroid cancer patients with lung metastases. Cell Physiol Biochem, 2016, 40(6): 1377-1390.
35.	Wang X, Zhang Q, Cai Z, et al. Identification of novel diagnostic biomarkers for thyroid carcinoma. Oncotarget, 2017, 8(67): 111551-111566.
36.	Xia S, Wang C, Ni X, et al. NONHSAT076754 aids ultrasonography in predicting lymph node metastasis and promotes migration and invasion of papillary thyroid cancer cells. Oncotarget, 2017, 8(2): 2293-2306.
37.	Liao D, Lv G, Wang T, et al. Prognostic value of long non-coding RNA BLACAT1 in patients with papillary thyroid carcinoma. Cancer Cell Int, 2018, 18: 47.
38.	Ma B, Liao T, Wen D, et al. Long intergenic non-coding RNA 271 is predictive of a poorer prognosis of papillary thyroid cancer. Sci Rep, 2016, 6: 36973.
39.	Luo YH, Liang L, He RQ, et al. RNA-sequencing investigation identifies an effective risk score generated by three novel lncRNAs for the survival of papillary thyroid cancer patients. Oncotarget, 2017, 8(43): 74139-74158.
40.	Li Q, Li H, Zhang L, et al. Identification of novel long non-coding RNA biomarkers for prognosis prediction of papillary thyroid cancer. Oncotarget, 2017, 8(28): 46136-46144.
41.	Guo LJ, Zhang S, Gao B, et al. Low expression of long non-coding RNA GAS5 is associated with poor prognosis of patients with thyroid cancer. Exp Mol Pathol, 2017, 102(3): 500-504.
42.	Zhou H, Sun Z, Li S, et al. LncRNA SPRY4-IT was concerned with the poor prognosis and contributed to the progression of thyroid cancer. Cancer Gene Ther, 2018, 25(1-2): 39-46.
43.	Xiong X, Zhu H, Chen X. Low expression of long noncoding RNA CASC2 indicates a poor prognosis and promotes tumorigenesis in thyroid carcinoma. Biomed Pharmacother, 2017, 93: 391-397.

1. Fr?hlich E, Wahl R. The current role of targeted therapies to induce radioiodine uptake in thyroid cancer. Cancer Treat Rev, 2014, 40(5): 665-674.
2. Ponting CP, Oliver PL, Reik W. Evolution and functions of long noncoding RNAs. Cell, 2009, 136(4): 629-641.
3. Klinge CM. Non-coding RNAs: long non-coding RNAs and microRNAs in endocrine-related cancers. Endocr Relat Cancer, 2018, 25(4): R259-R282.
4. Zhang R, Hardin H, Chen J, et al. Non-coding RNAs in thyroid cancer. Endocr Pathol, 2016, 27(1): 12-20.
5. Clemson CM, Hutchinson JN, Sara SA, et al. An architectural role for a nuclear noncoding RNA: NEAT1 RNA is essential for the structure of paraspeckles. Mol Cell, 2009, 33(6): 717-726.
6. Yu X, Li Z, Zheng H, et al. NEAT1: a novel cancer-related long non-coding RNA. Cell Prolif, 2017, 50(2): e12329.
7. Li JH, Zhang SQ, Qiu XG, et al. Long non-coding RNA NEAT1 promotes malignant progression of thyroid carcinoma by regulating miRNA-214. Int J Oncol, 2017, 50(2): 708-716.
8. Zhang H, Cai Y, Zheng L, et al. Long noncoding RNA NEAT1 regulate papillary thyroid cancer progression by modulating miR-129-5p/KLK7 expression. J Cell Physiol, 2018, 233(10): 6638-6648.
9. Sun W, Lan X, Zhang H, et al. NEAT1_2 functions as a competing endogenous RNA to regulate ATAD2 expression by sponging microRNA-106b-5p in papillary thyroid cancer. Cell Death Dis, 2018, 9(3): 380.
10. Zhang R, Hardin H, Huang W, et al. MALAT1 long non-coding RNA expression in thyroid tissues: analysis by in situ hybridization and real-time PCR. Endocr Pathol, 2017, 28(1): 7-12.
11. Chu YH, Hardin H, Schneider DF, et al. MicroRNA-21 and long non-coding RNA MALAT1 are overexpressed markers in medullary thyroid carcinoma. Exp Mol Pathol, 2017, 103(2): 229-236.
12. Huang JK, Ma L, Song WH, et al. MALAT1 promotes the proliferation and invasion of thyroid cancer cells via regulating the expression of IQGAP1. Biomed Pharmacother, 2016, 83: 1-7.
13. Huang JK, Ma L, Song WH, et al. LncRNA-MALAT1 promotes angiogenesis of thyroid cancer by modulating tumor-associated macrophage FGF2 protein secretion. J Cell Biochem, 2017, 118(12): 4821-4830.
14. Flockhart RJ, Webster DE, Qu K, et al. BRAF^V600E remodels the melanocyte transcriptome and induces BANCR to regulate melanoma cell migration. Genome Res, 2012, 22(6): 1006-1014.
15. Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer, 2013, 13(3): 184-199.
16. Wang Y, Guo Q, Zhao Y, et al. BRAF-activated long non-coding RNA contributes to cell proliferation and activates autophagy in papillary thyroid carcinoma. Oncol Lett, 2014, 8(5): 1947-1952.
17. Wang Y, Gu J, Lin X, et al. lncRNA BANCR promotes EMT in PTC via the Raf/MEK/ERK signaling pathway. Oncol Lett, 2018, 15(4): 5865-5870.
18. Zheng H, Wang M, Jiang L, et al. BRAF-activated long noncoding RNA modulates papillary thyroid carcinoma cell proliferation through regulating thyroid stimulating hormone receptor. Cancer Res Treat, 2016, 48(2): 698-707.
19. Liao T, Qu N, Shi RL, et al. BRAF-activated LncRNA functions as a tumor suppressor in papillary thyroid cancer. Oncotarget, 2017, 8(1): 238-247.
20. Liu L, Yang J, Zhu X, et al. Long noncoding RNA H19 competitively binds miR-17-5p to regulate YES1 expression in thyroid cancer. FEBS J, 2016, 283(12): 2326-2339.
21. Liu N, Zhou Q, Qi YH, et al. Effects of long non-coding RNA H19 and microRNA let7a expression on thyroid cancer prognosis. Exp Mol Pathol, 2017, 103(1): 71-77.
22. Wang P, Liu G, Xu W, et al. Long noncoding RNA H19 inhibits cell viability, migration, and invasion via downregulation of IRS-1 in thyroid cancer cells. Technol Cancer Res Treat, 2017, 16(6): 1102-1112.
23. Lan X, Sun W, Dong W, et al. Downregulation of long noncoding RNA H19 contributes to the proliferation and migration of papillary thyroid carcinoma. Gene, 2018, 646: 98-105.
24. Pan W, Zhou L, Ge M, et al. Whole exome sequencing identifies lncRNA GAS8-AS1 and LPAR4 as novel papillary thyroid carcinoma driver alternations. Hum Mol Genet, 2016, 25(9): 1875-1884.
25. Zhang D, Liu X, Wei B, et al. Plasma lncRNA GAS8-AS1 as a potential biomarker of papillary thyroid carcinoma in Chinese patients. Int J Endocrinol, 2017, 2017: 2645904.
26. Qin Y, Sun W, Zhang H, et al. LncRNA GAS8-AS1 inhibits cell proliferation through ATG5-mediated autophagy in papillary thyroid cancer. Endocrine, 2018, 59(3): 555-564.
27. Jendrzejewski J, He H, Radomska HS, et al. The polymorphism rs944289 predisposes to papillary thyroid carcinoma through a large intergenic noncoding RNA gene of tumor suppressor type. Proc Natl Acad Sci U S A, 2012, 109(22): 8646-8651.
28. Jendrzejewski J, Thomas A, Liyanarachchi S, et al. PTCSC3 is involved in papillary thyroid carcinoma development by modulating S100A4 gene expression. J Clin Endocrinol Metab, 2015, 100(10): E1370-E1377.
29. Wang X, Lu X, Geng Z, et al. LncRNA PTCSC3/miR-574-5p governs cell proliferation and migration of papillary thyroid carcinoma via Wnt/β-catenin signaling. J Cell Biochem, 2017, 118(12): 4745-4752.
30. Wang XM, Liu Y, Fan YX, et al. LncRNA PTCSC3 affects drug resistance of anaplastic thyroid cancer through STAT3/INO80 pathway. Cancer Biol Ther, 2018, 19(7): 590-597.
31. Lan X, Zhang H, Wang Z, et al. Genome-wide analysis of long noncoding RNA expression profile in papillary thyroid carcinoma. Gene, 2015, 569(1): 109-117.
32. Lan X, Sun W, Zhang P, et al. Downregulation of long noncoding RNA NONHSAT037832 in papillary thyroid carcinoma and its clinical significance. Tumour Biol, 2016, 37(5): 6117-6123.
33. Sun W, Lan X, Wang Z, et al. Overexpression of long non-coding RNA NR_036575.1 contributes to the proliferation and migration of papillary thyroid cancer. Med Oncol, 2016, 33(9): 102.
34. Qiu ZL, Shen CT, Sun ZK, et al. Circulating long non-coding RNAs act as biomarkers for predicting ¹³¹I uptake and mortality in papillary thyroid cancer patients with lung metastases. Cell Physiol Biochem, 2016, 40(6): 1377-1390.
35. Wang X, Zhang Q, Cai Z, et al. Identification of novel diagnostic biomarkers for thyroid carcinoma. Oncotarget, 2017, 8(67): 111551-111566.
36. Xia S, Wang C, Ni X, et al. NONHSAT076754 aids ultrasonography in predicting lymph node metastasis and promotes migration and invasion of papillary thyroid cancer cells. Oncotarget, 2017, 8(2): 2293-2306.
37. Liao D, Lv G, Wang T, et al. Prognostic value of long non-coding RNA BLACAT1 in patients with papillary thyroid carcinoma. Cancer Cell Int, 2018, 18: 47.
38. Ma B, Liao T, Wen D, et al. Long intergenic non-coding RNA 271 is predictive of a poorer prognosis of papillary thyroid cancer. Sci Rep, 2016, 6: 36973.
39. Luo YH, Liang L, He RQ, et al. RNA-sequencing investigation identifies an effective risk score generated by three novel lncRNAs for the survival of papillary thyroid cancer patients. Oncotarget, 2017, 8(43): 74139-74158.
40. Li Q, Li H, Zhang L, et al. Identification of novel long non-coding RNA biomarkers for prognosis prediction of papillary thyroid cancer. Oncotarget, 2017, 8(28): 46136-46144.
41. Guo LJ, Zhang S, Gao B, et al. Low expression of long non-coding RNA GAS5 is associated with poor prognosis of patients with thyroid cancer. Exp Mol Pathol, 2017, 102(3): 500-504.
42. Zhou H, Sun Z, Li S, et al. LncRNA SPRY4-IT was concerned with the poor prognosis and contributed to the progression of thyroid cancer. Cancer Gene Ther, 2018, 25(1-2): 39-46.
43. Xiong X, Zhu H, Chen X. Low expression of long noncoding RNA CASC2 indicates a poor prognosis and promotes tumorigenesis in thyroid carcinoma. Biomed Pharmacother, 2017, 93: 391-397.

Previous Article
TERT 啟動子突變與甲狀腺乳頭狀癌臨床病理學特征關系的研究進展
Next Article
Protective effect of apocynin on lung injury induced by acute necrotic pancreatitis in rat

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

長鏈非編碼RNA與甲狀腺癌發生發展關系的研究進展及其臨床價值

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content